肿瘤疫苗是目前医学研究的一大热点,肿瘤疫苗研制中存在的一个主要问题便是大多数肿瘤的免疫原性很弱。树突状细胞(DC)是体内功能最强的抗原递呈细胞,由DC激活的T细胞免疫在抗肿瘤过程中起着主导作用。因此,DC肿瘤疫苗的兴起及其临床应用的结果均显示出DC疫苗在恶性肿瘤治疗中巨大应用前景,尤其是对于手术效果差、易复发的脑内胶质瘤来讲,具有更为重要的意义。本文就此作一综述。 Tumor vaccine is a hot topic in medical research at present. One of the major problems in the development of tumor vaccines is that most tumors have weak immunogenicity. Dendritic cells (DCs) are the most potent antigen presenting cells in the body. T cell immunity activated by DC plays a leading role in the anti-tumor process. Therefore, the rise of DC tumor vaccine and its clinical application results show that DC vaccine has great application prospect in the treatment of malignant tumors, especially for poorly operated and easily recurring brain glioma, which is even more important significance. This article gives a summary of this.